4164.SR

Full House

Nahdi Medical Company · Healthcare · Saudi Arabia · $3.2B cap · $3.2M/day traded

SAR 93.00 +2.5% · close 5 Nov · scored 7 Nov

Full House: Strong business, sensible price, and the market agrees.

89
Score
Get score alerts
Quality
71
Value
63
Momentum
56

As of 7 Nov 2026, the MoatMap Score for Nahdi Medical Company (4164.SR) is 89/100, ranked against 25,000+ stocks in 38 markets (Quality 71, Value 63, Momentum 56, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
15.3x
peers 16.3x
ROE
30.6%
peers 13.9%
D/E
0.7x
peers 0.5x
Dividend %
3.3%
trailing yield

ABOUT NAHDI MEDICAL COMPANY

Read

Nahdi Medical Company, together with its subsidiaries, engages in the wholesale and retail trading of cosmetics, pharmaceutical, special and healthy foods, and medical equipment products in the Kingdom of Saudi Arabia and the United Arab Emirates.

FINANCIAL SUMMARY (SAR)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue8.6B8.7B9.4B10.2B5.8%11.1B10.9B11.7B6.9%
EPS (SAR)6.836.876.316.39-2.2%6.256.366.662.1%
Shares130.0M130.0M130.0M130.0M0.0%130.0M———
Debt1.2B1.2B1.5B1.8B15.1%1.8B———
Equity2.2B2.5B2.6B2.7B6.9%————
Op CF1.7B1.3B1.5B1.1B-12.1%1.6B———
Inv CF-275.1M-331.6M-328.0M-354.3M—————
Fin CF-717.3M-1.2B-1.1B-1.2B—————
PRICE (1Y) · SAR+1.6%
82.084.887.590.393.027 Sep18 Oct5 Nov
SMA 50SMA 200
Price checkStill fallingExperimental

Made a new 52-week low 9 trading days ago, 16% below its 52-week high. The fall has not stopped yet.

The Momentum score still reads 56: it looks back six months, so it has not caught up with this fall.

SwingsCalm

Calmer than 81% of stocks we rank over the past year (volatility 26% a year).

How this is worked out

The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
SAR 93.00
RSI (14)
56.7
52-Week Range-15.7% from high
Low SAR 81.10High SAR 110.35

SCORE BREAKDOWN

Quality
71
ROIC
20.6%90.2
ROE
30.6%94.6
GP/Assets
58.5%90.7
Op. Margin
7.3%55.9
FCF/Assets
10.7%87.0
Piotroski
549.2
Int. Cover
10.6x62.8
D/E Ratio
0.66x22.4
Current Ratio
1.37x22.2
Value
63
P/E (TTM)
15.3x70.7
EV/EBITDA
10.8x63.9
P/FCF
16.9x63.5
P/B
4.5x27.6
P/S
1.1x80.5
Div Yield
3.3%76.8
Momentum
56
52W High %
84%76.7
RS 6M
0%58.8
SMA 50/200
0.96x51.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+16%32.5
Q Growth
7%44.4

FUNDAMENTALS

Market Cap
$3.2B
P/E (Forward)
13.2x
Gross Margin
35.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4164.SR are excluded.

TickerCompanyMkt CapScore
4164.SRNahdi Medical Company(you)$3.2B89
4163.SRAl-Dawaa Medical Services Company$847M74
4002.SRMouwasat Medical Services Company$2.9B85
4015.SRJamjoom Pharmaceuticals Factory Company$2.1B81
2230.SRSaudi Chemical Holding Company$1.4B79
9600.SRQomel Company Limited$63M26
4016.SRMiddle East Pharmaceutical Industries Company$604M80
2070.SRSaudi Pharmaceutical Industries and Medical Appliances Corporation$759M74
4019.SRSpecialized Medical Company$875M69
4005.SRNational Medical Care Company$1.2B62

Peer medians: ROE 13.9% · P/E 16.3x · Gross margin 31.2%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Nahdi Medical Company (4164.SR): Stock Score Summary

Nahdi Medical Company (4164.SR) has a MoatMap Score of 89/100 based on Quality (71/100), Value (63/100), and Momentum (56/100) factor scores.

Nahdi Medical Company, together with its subsidiaries, engages in the wholesale and retail trading of cosmetics, pharmaceutical, special and healthy foods, and medical equipment products in the Kingdom of Saudi Arabia and the United Arab Emirates.

Key Financial Metrics

PriceSAR 93.00
Market Cap$3.2B
P/E (TTM)15.35
P/E (Forward)13.19
Price/Book4.49
Return on Equity30.6%
Return on Invested Capital20.6%
Debt/Equity0.66x
Gross Margin35.3%
Operating Margin7.3%
Revenue Growth9.4%
Dividend Yield3.3%
Free Cash Flow$191M

Nahdi Medical Company operates in the Pharmaceutical Retailers industry, part of the Healthcare sector (Saudi Arabia).

Frequently Asked Questions

What is Nahdi Medical Company’s (4164.SR) MoatMap Score?
The MoatMap Score for Nahdi Medical Company (4164.SR) is 89/100. It is a composite of Quality (71), Value (63), and Momentum (56), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Nahdi Medical Company have an economic moat?
Nahdi Medical Company (4164.SR) has a Quality factor score of 71/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Nahdi Medical Company in?
Nahdi Medical Company (4164.SR) operates in the Healthcare sector, specifically the Pharmaceutical Retailers industry (Saudi Arabia).